Neurología
Evidencia clínica internacional para hirudoterapia en enfermedad cerebrovascular, dolor neuropático y rehabilitación neurológica
Investigational / Research Priority
Neurological applications of hirudotherapy are not included in the FDA 510(k) clearance for medicinal leeches. The evidence below reflects international clinical experience published in peer-reviewed literature.
Investigational Application
International Clinical Evidence
Neurological applications of hirudotherapy encompass ischemic stroke (acute and rehabilitative), chronic cerebrovascular insufficiency, radiculopathy, traumatic brain injury, peripheral nerve disorders, and myofascial pain syndromes. International clinical experience, documented across more than 20 published investigations involving over 1,500 patients, provides the foundation for ongoing research interest. The biological rationale rests on four pharmacological properties of leech SGSry gland secretion (SGS): anticoagulant/rheological, microcirculatory, neurotrophic, and anti-inflammatory mechanisms.
All currently available evidence derives from uncontrolled case series and non-randomized controlled comparisons. No randomized controlled trials have been conducted for any neurological indication. Hirudotherapy should be considered only as an investigational adjunct to established neurological care, not as a substitute for evidence-based interventions such as thrombolysis, anticoagulation, or surgical decompression.
Fundamento biológico
Anticoagulant & Rheological
Hirudin (Kd = 20 fM) blocks thrombin. Apyrase removes ADP aggregation stimulus — 17% reduction in platelet aggregation measured in stroke patients. Calin/saratin inhibit platelet adhesion. Lipases reduce blood lipids. Relevant to stroke and hypercoagulable states.
Microcirculatory Enhancement
Hyaluronidase increases tissue permeability for SGS distribution and edema drainage. Histamine-like vasodilators promote capillary dilation. Relevant to compression neuropathies, post-ischemic edema, and documented Doppler improvement.
Neurotrophic Activity
Destabilase-M stimulates neurite outgrowth at 10-12 to 10-14 M. Bdellastatin, Bdellin-B, and Eglin c also promote neurite growth. Not cited in clinical studies — a major science-practice gap with high translational potential.
Anti-Inflammatory & Analgesic
Eglins/bdellins inhibit neutrophil proteinases. Kininases degrade bradykinin (pain signaling). LDTI blocks mast cell tryptase. Relevant to radiculopathy, myofascial pain, and post-traumatic neuroinflammation.
Ictus isquémico y enfermedad cerebrovascular
The largest neurological evidence base concerns cerebrovascular disease, with over 200 patients across six investigations (1997-2003). Seselkina et al. (1997-1999) documented functional recovery in acute hemispheric stroke: speech restoration in 78%, visual function recovery in 74%, swallowing improvement in 42%, along with improved transcranial Doppler flow velocity, EEG improvement, and a 17% reduction in ADP-induced platelet aggregation.
78%
Speech Restoration
Seselkina et al. 1997-1999
74%
Visual Recovery
Seselkina et al. 1997-1999
42%
Swallowing Improvement
Seselkina et al. 1997-1999
Mokhov and Zaltsman (1998) independently confirmed: reduced headache, tinnitus, and focal signs; sustained BP reduction of 20-30 mmHg. Frolov and Frolova (1999) treated 89 patients in rehabilitation — 31% achieved full motor recovery. Additional studies documented antiplatelet effects in chronic posterior circulation ischemia (n=22) and recommended HT for stroke prevention in hypercoagulable patients.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Seselkina et al. 1999 | Case series, uncontrolled | Hemispheric ischemic stroke (n=NR) | 5-8 leeches at acupuncture points, 1-3x/week, 2-3 week course | Functional recovery across multiple domains | Speech 78%; vision 74%; swallowing 42%; 17% platelet aggregation reduction; improved Doppler flow; EEG improvement Publications 1997-1999; multimodal treatment; no comparator; Level 4 |
| Mokhov & Zaltsman 1998 | Case series, uncontrolled | Ischemic stroke with hypertension (n=NR) | 6-8 leeches, 8-15 sessions, 1-2 day intervals; mastoid or C1-C2 placement | Neurological deficits, blood pressure | Reduced headache, tinnitus; regression of focal signs; sustained BP reduction 20-30 mmHg Independent confirmation; Level 4 |
| Frolov & Frolova 1999 | Case series, combined intervention | Ischemic stroke sequelae (rehabilitation) (n=89) | HT + reflex therapy, pharmacotherapy, massage, PT | Motor recovery | 31% full motor recovery (28/89); others 1-4 points on strength scale Largest rehabilitation cohort; combined intervention; Level 4 |
| Dolgo-Saburov & Shklyaev 2000 | Case series, uncontrolled | Cerebrovascular disease (n=35) | HT course (protocol not specified) | Symptoms, labs, rheoencephalography | Improvement trends in symptoms, labs, and REG findings Level 4 |
| Pospelova & Barnaulova 2003 | Case series, uncontrolled | Chronic posterior circulation ischemia (n=22) | Leeches over vertebral artery, mastoid, occipital; 10 sessions, 1-2x/week | Symptoms, psychoemotional state, platelet aggregation | Significant symptom improvement; measurable antiplatelet effect Level 4 |
| Poprotsky et al. 2001 | Case series, combined intervention | Chronic cerebrovascular disease (n=NR) | HT integrated into inpatient rehabilitation | Medication requirement, adverse reactions | Reduced allergic reactions and medication use Sanatorium-based; Level 4 |
Evidence Assessment
Radiculopatía vertebrogénica y dolor espinal
Radiculopathy has the most favorable evidence profile, with over 500 patients across seven studies including one controlled comparison. Konyrtaeva and Tulesarinov (1999) treated 280 patients with MRI/CT-confirmed disc pathology — 89% positive clinical effect with documented disc herniation size reduction and pain resolution.
HT + Manual Therapy (n=30)
1-3 years
Remission duration
100% response if disease <1 year
Manual Therapy Alone (n=7)
6-8 months
Remission duration
Arutyunov et al. 1998 — Level 3
Arutyunov et al. (1998) provided the strongest controlled evidence: 37 patients with MRI-confirmed disc extrusions 3-9 mm received sequential placement at nerve root exits, ligaments, trigger points, and facet joints. Remission of 1-3 years (HT group) versus 6-8 months (control) — the largest effect size in the neurological HT literature.
GRADE Evidence Level: Low
Observational studies or RCTs with serious limitations
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Konyrtaeva & Tulesarinov 1999 | Case series, uncontrolled | Disc herniation/protrusion (radiography, CT, MRI confirmed) (n=280) | 8-12 sessions, daily or every other day | Clinical response, disc herniation size, pain | 89% clinical improvement; disc herniation reduction; pain resolution Largest spinal cohort in HT literature; Level 4 |
| Arutyunov et al. 1998 | Controlled comparison (non-randomized) | Chronic radiculopathy; MRI disc extrusions 3-9 mm (n=37) | 7-9 leeches at nerve roots, ligaments, trigger points, facets; every 3-4 days; 6-9 sessions; manual therapy next day | Remission duration | Remission 1-3 yr (HT+MT, n=30) vs 6-8 mo (MT alone, n=7); 100% response if <1 yr disease Strongest controlled radiculopathy evidence; Level 3 |
| Filimonova 1999 | Case series, combined intervention | Vertebrogenic conditions (n=64) | HT as part of comprehensive treatment | Pain, ROM, posture, vascular tone | Clinical improvement in virtually all patients Combined intervention; Level 4 |
| Mokhov & Zaltsman 1998 | Case series, uncontrolled | Cervicothoracic/lumbosacral radicular syndrome (n=8) | 4-6 leeches paravertebrally and along nerve root | Symptom regression | Near-complete regression 63% (5/8); incomplete in 37% (3/8) Small sample; Level 4 |
| Arutyunov et al. 1997 | Case series, combined intervention | Upper thoracic scoliosis (n=67) | HT + manual therapy; 1-4 sessions; 5-9 leeches | Clinical improvement | Improvement in all cases Level 4 |
| Frolov & Frolova 1999 | Case series, combined intervention | Shoulder periarthritis + myofascial trigger points (Muzalevsky n=31) (n=29) | 6-10 leeches periarticular, 1-2x/week, 8-10 sessions + MT | Clinical effectiveness, pain, edema | Effective; foci series: pain relief, edema resolution Level 4 |
Evidence Assessment
Traumatismo craneoencefálico
Azarova et al. (2001) included HT in rehabilitative treatment of 61 patients with closed craniocerebral injury sequelae, with a control group of 34 patients receiving rehabilitation without HT. One to five leeches were applied 20-30 minutes daily or every other day to temporal, mastoid, occipital, and collar zones. Rheographic parameters demonstrated statistically significant improvement in the HT group — one of only three neurological studies to include a control group.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Azarova et al. 2001 | Controlled comparison (non-randomized) | Closed craniocerebral injury sequelae (n=95) | 1-5 leeches 20-30 min, daily/every other day; temporal, mastoid, occipital, collar zone (n=61 HT; n=34 control) | Rheographic parameters | Significant improvement in rheographic parameters vs control Only controlled TBI study; Level 3 |
Trastornos de nervios periféricos
Three peripheral nerve conditions have been studied. Farber (1985) treated 80 patients with facial nerve paralysis — hospital stay reduced by 5.2 days versus historical controls, attributed to edema reduction. HT was particularly indicated with coexisting hypertension. Kasimov (1990) treated 50 patients with sciatic nerve neuritis using a distinct high-dose protocol (5-16 leeches per session, 10-minute application, avg 45 total leeches), with shortened recovery times. Zhavoronkova (1995-1999) documented pain resolution in meralgia paresthetica (lateral cutaneous nerve entrapment).
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Farber 1985 | Case series, historical comparison | Peripheral facial nerve paralysis (n=80) | Leeches every other day to mastoid process; 4-10 sessions | Hospital length of stay | Hospital stay reduced from 28.8 to 23.6 days (5.2-day reduction) Especially indicated with hypertension; Level 4 |
| Kasimov 1990 | Case series, uncontrolled | Sciatic nerve neuritis/neuralgia (n=50) | 5-16 leeches/session, 10-min along nerve course; 2-8 sessions; avg 45 total leeches | Recovery time | Considerably shortened recovery times Published in Baskova guidelines; Level 4 |
| Zhavoronkova 1999 | Case series | Meralgia paresthetica (Roth-Bernhardt disease) (n=NR) | HT (protocol details limited) | Paresthesia, pain episodes | Pain disappearance in lateral thigh; reduced pain episodes Level 4 |
Síndromes de dolor miofascial
Published research documents over 290 patients across two study groups. Krymskaya et al. (1997-2001) treated 54+ patients with myofascial pain, fibromyalgia, and facial pain syndromes — pain reduction after first sessions, BP stabilization, and elimination of pathological components in 14 facial cases.
Frolov et al. (2003) treated 237 patients with foot/lower leg myofascial pain — the largest myofascial cohort in HT literature. A sequential comparison demonstrated that HT plus manual therapy produced more pronounced and lasting pain reduction than manual therapy alone. Direct trigger-point application allows localized delivery of anti-inflammatory and analgesic SGS compounds.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Krymskaya et al. 2001 | Case series / combined intervention | Myofascial pain, fibromyalgia, facial pain syndromes (n=54) | 6-8 leeches over trigger points, 5-6 sessions at 2-3 day intervals; + procaine/hydrocortisone for indurations | Pain, fibromyalgia sites, BP | Pain relief after first sessions; BP stabilization; eliminated pathological components in 14 facial cases Publications 1997-2001; Level 4 |
| Frolov et al. 2003 | Sequential comparison | Foot/lower leg myofascial pain (n=237) | 79 pts with residual indurations: 3-7 leeches, 1-2x/week, 3-7 sessions after initial manual therapy | Pain reduction, durability | HT + MT superior to MT alone — more pronounced and lasting pain reduction Largest myofascial cohort; Level 3 |
Aplicaciones históricas y psiquiátricas
Historical literature documents extensive use dating to the mid-20th century. Lukashev (1948) treated 616 patients across diverse neurological diagnoses. Yasnopolskaya (1983) applied HT to atherosclerotic psychoses — best results in affective and cerebrasthenic syndromes. Voloshina and Bukhanovskaya (2001) treated 24 psychiatric patients with combined therapy — BP stabilization, sleep improvement, and positive emotional shifts with no complications. All historical and psychiatric evidence is Level IV, insufficient for clinical recommendations, and presented for completeness only.
GRADE Evidence Level: Very Low
Case reports, case series, or expert opinion only
| Study | Design | Population (n=) | Intervention | Key Outcome | Result |
|---|---|---|---|---|---|
| Lukashev 1948 | Case series | Mixed neurological/psychiatric diagnoses (n=616) | HT (protocol not specified) | Clinical response across diagnoses | Positive results across all categories Historical; Level 4 |
| Voloshina & Bukhanovskaya 2001 | Case series, combined intervention | Psychiatric: depression (10), opioid use (4), schizophrenia (2), other (8) (n=24) | 10-15 sessions 2-3x/week; collar, retroauricular, temporal, frontal areas; + pharma/physio/psychotherapy | BP, headache, sleep, emotional measures | BP stabilization; headache resolution; sleep improved; positive emotional shifts; no complications Combined intervention; Level 4 |
Compuestos neurotróficos de la SGS
| Compound | Activity | Neurological Relevance |
|---|---|---|
| Destabilase-M | Neurite outgrowth at 10-12-10-14 M | Post-stroke neural repair; TBI axonal regeneration |
| Bdellastatin | Neurite growth-promoting; trypsin inhibitor | Neuroprotection in inflammatory disease |
| Bdellin-B | Neurite growth-promoting; trypsin/plasmin inhibitor | Anti-inflammatory neuroprotection; tPA modulation |
| Eglin c | Neurite growth-promoting; elastase inhibitor | BBB protection; neutrophil damage attenuation |
Protocolos clínicos
Synthesized from published investigations for educational and research reference. All neurological applications require concurrent standard neurological care.
Patient Selection
Ischemic Stroke
- Hemispheric ischemic infarction; not comatose
- Acute phase or rehabilitation period
- Concurrent standard stroke management required
- No hemorrhagic stroke, active hemorrhage, or concurrent thrombolysis
Radiculopathy
- MRI/CT-confirmed disc herniation or protrusion
- Chronic pain with frequent exacerbations
- Incomplete response to conservative therapy
- Best outcomes with disease duration under 1 year
TBI / Peripheral Nerve
- TBI: sequelae of closed injury; rehabilitation phase; autonomic disturbances
- Facial paralysis (especially with hypertension)
- Sciatic neuritis/neuralgia; entrapment neuropathies
Pre-Procedure Assessment
- NIHSS (stroke), VAS (pain), muscle strength grading
- Brain/spinal imaging (CT/MRI); transcranial Doppler; EEG
- CBC, coagulation panel (PT, aPTT, INR, fibrinogen), lipid panel
- Medication review: anticoagulants, antiplatelets, thrombolytics
Procedure by Indication
Ischemic Stroke
- Leeches: 5-8/session
- Sites: Vertebrobasilar — paravertebral C1-C2; ICA — mastoid on affected side; acupuncture points
- Frequency: 1-3x/week
- Course: 5-15 sessions over 2-4 weeks
- Duration: Full engorgement
Radiculopathy
- Leeches: 4-9/session
- Sites (sequential): Nerve root exits, interspinous ligaments, paravertebral trigger points, facet joints, nerve root course
- Frequency: Every 3-4 days
- Course: 6-12 sessions over 3-5 weeks
- Adjunct: Gentle manual therapy next day
TBI Rehabilitation
- Leeches: 1-5/session; temporal, mastoid, occipital, collar zone
- Duration: 20-30 min (not full engorgement — distinct protocol)
- Frequency: Daily or every other day
Peripheral Nerve & Myofascial
- Facial paralysis: 4-6 leeches to mastoid, every other day, 4-10 sessions (especially with hypertension)
- Sciatic nerve: 5-16 leeches along nerve course, 10-min application, 2-8 sessions (avg 45 total)
- Myofascial pain: 3-8 leeches at trigger points, 1-2x/week, 3-8 sessions; may add procaine/hydrocortisone for indurations
Post-Procedure Monitoring
- Neurological reassessment: Motor function, speech, cranial nerves (stroke); pain/ROM (radiculopathy); standardized scales at each session
- Imaging: Transcranial Doppler and follow-up EEG at course completion (cerebrovascular patients)
- Blood pressure: Pre- and post-session (documented 20-30 mmHg reduction expected)
- Labs: Coagulation panel (PT/INR, aPTT) if concurrent anticoagulation; blood viscosity; hemoglobin for extended courses
- Wound care: Sterile dressing; 4–24 hr oozing expected; Aeromonas prophylaxis for immunocompromised
Expected Outcomes
- Stroke: 31% full motor recovery; 78% speech, 74% vision recovery; BP reduction 20-30 mmHg; improved cerebral blood flow
- Radiculopathy: 89% clinical improvement (n=280); remission 1-3 yr with MT vs 6-8 mo without; best outcomes <1 yr disease
- TBI: Improved rheographic parameters and autonomic regulation
- Facial paralysis: Hospital stay reduced by 5.2 days
- Myofascial pain: Pain relief often after first sessions; HT + MT more lasting than MT alone
Estatus regulatorio
Consideraciones de seguridad
Contraindications
- Hemorrhagic stroke: Anticoagulant SGS effects absolutely contraindicated with active cerebral hemorrhage
- Comatose patients: Per Seselkina et al. (1999) — HT not for patients in coma
- Active intracranial hemorrhage: Including hemorrhagic transformation of ischemic stroke
- Concurrent thrombolysis (tPA): Absolute contraindication — unacceptable hemorrhagic risk
- Severe uncontrolled hypertension: Systolic >220 mmHg — stabilize before initiating
- Large completed infarction with cerebral edema: Risk of hemorrhagic conversion
Drug Interactions
- Anticoagulants (warfarin, DOACs, heparin): Additive anticoagulation — dose coordination and enhanced monitoring required, especially for AF/DVT prophylaxis in stroke
- Antiplatelets (aspirin, clopidogrel): Additive platelet inhibition compounds the 17% ADP aggregation reduction — monitor platelet function
- Thrombolytics (alteplase, tenecteplase): Absolute contraindication — never administer concurrently
- Antiepileptics: No direct interaction; check platelets if on valproate
- Corticosteroids: Immunosuppression may increase bite-site infection risk — consider Aeromonas prophylaxis
- Opioid analgesics: No direct interaction; HT pain reduction may allow dose reduction
Brechas de evidencia y prioridades de investigación
Gaps
- No RCTs for any neurological indication
- Multimodal protocols prevent attribution of outcomes
- Natural stroke recovery confounds interpretation
- SGS neurotrophic properties not cited in any clinical study
- No neurotrophic biomarker measurement in treated patients
- Wide protocol variation (1-16 leeches/session) suggests need for optimization
Research Priorities
- RCT: HT adjunct to standard stroke rehabilitation (NIHSS/mRS)
- RCT: HT + MT vs MT alone for MRI-confirmed lumbar radiculopathy
- Translational: SGS neurotrophic compound levels at application sites
- Pharmacokinetic: SGS distribution to neural tissue
- Priority order: radiculopathy (best evidence), stroke (largest base), neurotrophic mechanisms (translational potential)
Conclusiones clave
Broadest specialty scope: Over 1,500 patients across 20+ published investigations spanning six neurological domains — the widest range of any specialty in the hirudotherapy literature.
Radiculopathy — strongest evidence: Controlled comparison (Arutyunov 1998) demonstrated 1-3 year remission vs 6-8 months. Large cohort (n=280) showed 89% positive response. Best RCT candidate.
Neurotrophic gap: Destabilase-M, Bdellastatin, Bdellin-B, and Eglin c demonstrate neurotrophic activity in laboratory studies but were never cited in clinical research — the highest-priority translational opportunity.
Safety-critical population: Concurrent anticoagulants, antiplatelets, and thrombolytics create particular risks. Hemorrhagic stroke and comatose state are absolute contraindications. BP monitoring essential given documented 20-30 mmHg reduction.
Sound biological rationale: Four mechanism domains (anticoagulant, microcirculatory, neurotrophic, anti-inflammatory) provide coherent molecular basis. Documented physiological endpoints include 17% platelet aggregation reduction and improved transcranial Doppler flow.
Investigational only: All evidence Level 3-4. No RCTs exist. Recovery rates cannot be attributed to HT alone. All applications are investigational adjuncts to standard care — not alternatives to thrombolysis, anticoagulation, or surgical intervention.
Recursos relacionados
Clinical Specialties
All 14 medical specialties reviewed.
Más información →
Endocrinology
Thyroid disorders and metabolic disease.
Más información →
Salivary Gland Secretion
SGS compounds including neurotrophic factors.
Más información →
Proteinase Inhibitors
Eglins, bdellins, and LDTI.
Más información →
All Indications
Complete indication list with evidence tiers.
Más información →